Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 15;16(10):5749-5762.
doi: 10.62347/LXNH6644. eCollection 2024.

Efficacy of Sarcupyrine/valsartan in the treatment of acute myocardial infarction: a meta-analysis

Jianfei Ye  1 , Weifen Zheng  1 , Mingming Zhang  1 , Bei Zhou  2 , Ying Fu  3 , Huanhao Mao  2
Affiliations
Review

Efficacy of Sarcupyrine/valsartan in the treatment of acute myocardial infarction: a meta-analysis

Jianfei Ye et al. Am J Transl Res. .

Abstract

Objective: To assess the efficacy of sacubitril-valsartan in the treatment of acute myocardial infarction (AMI) using meta-analysis methods.

Methods: Relevant papers on sacubitril/valsartan for treating AMI were searched on PubMed, Embase, Medical Literature Analysis, and Retrieval System On-Line (MEDLINE), Science Direct, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journal Database, and Chinese Biomedical Literature Database (CBM). The time range was from their inception to February 1, 2023.

Results: A total of 10 articles involving 13,135 patients were included for this meta-analysis according to the inclusion and exclusion criteria. Among these patients, 6,581 were treated with sacubitril/valsartan, as the experimental group, and the other 6,554 patients were classified into the control group. After treatment, the risk of hospitalization for heart failure (HF) in the experimental group was lower than that of the control group (OR=0.77, 95% CI: 0.67-0.88, P=0.0002); the average left ventricular end diastolic diameter (LVEDD) (MD=-5.56, 95% CI: -7.92-3.20, P<0.0001) was significantly higher and 6-minute-walk distance (6MWD) (MD=95.86, 95% CI: 30.57-161.16, P=0.004) was significantly longer in the treatment group than in the control group. Besides, the left ventricular ejection fraction (LVEF) (MD=2.99, 95% CI: 0.47-5.51, P=0.02) was significantly lower than that of the control group.

Conclusion: Sacubitril/Valsartan improves cardiac function in patients with AMI, reduces the risk of postoperative myocardial reinfarction, and reduces the risk of hospitalization for HF.

Keywords: Sacubitril/valsartan; acute myocardial infarction; effectiveness analysis; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
The process for screening eligible studies.
Figure 2
Figure 2
Bias risk of the included literature.
Figure 3
Figure 3
Summary of bias risk. Note: +, -, and ? refer to low, high, and unclear risk, respectively.
Figure 4
Figure 4
Forest plot of posttreatment mortality of patients.
Figure 5
Figure 5
Funnel plot of studies reporting post-treatment mortality.
Figure 6
Figure 6
Forest plot of myocardial re-infarction counts after treatment.
Figure 7
Figure 7
Funnel plot of studies reporting myocardial reinfarction counts.
Figure 8
Figure 8
Forest plot of risk of heart failure (HF) hospitalization.
Figure 9
Figure 9
Funnel plot of studies reporting heart failure (HF) hospitalization.
Figure 10
Figure 10
Forest plot of 6-minute walking distance (6MWD).
Figure 11
Figure 11
Galbraith heterogeneity test results for the 6-minute walking distance (6MWD).
Figure 12
Figure 12
Funnel plot of studies reporting 6-minute walking distance (6MWD).
Figure 13
Figure 13
Forest plot of left ventricular ejection fraction (LVEF).
Figure 14
Figure 14
Galbraith heterogeneity for left ventricular ejection fraction (LVEF).
Figure 15
Figure 15
Funnel plot of studies reporting left ventricular ejection fraction (LVEF).
Figure 16
Figure 16
Forest plot of left ventricular end-diastolic diameter (LVEDD).
Figure 17
Figure 17
Galbraith heterogeneity test results in left ventricular end-diastolic diameter (LVEDD).
Figure 18
Figure 18
Funnel plot of studies reporting left ventricular end-diastolic diameter (LVEDD).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Guan T, Zhu X, Tian L, Shen T. Evaluation of the effect of nano-sodium alginate-bioglass on cardiac function of myocardial infarction based on cardiac ultrasound. Cell Mol Biol (Noisy-le-grand) 2022;68:67–76. - PubMed
    1. Ibrahim NE, Piña IL, Camacho A, Bapat D, Felker GM, Maisel AS, Butler J, Prescott MF, Abbas CA, Solomon SD, Januzzi JL Jr Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Investigators. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Eur J Heart Fail. 2020;22:2018–2025. - PMC - PubMed
    1. Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR PARALLAX Investigators and Committee members. Effect of sacubitril/valsartan vs. standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021;326:1919–1929. - PMC - PubMed
    1. Salinas-Casado J, Méndez-Rubio S, Esteban-Fuertes M, Gómez-Rodríguez A, Vírseda-Chamorro M, Luján-Galán M, Rituman G. Efficacy and safety of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections. Arch Esp Urol. 2018;71:169–177. - PubMed
    1. Senni M, Wachter R, Witte KK, Straburzynska-Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Chakrabarti A, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D TRANSITION Investigators. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020;22:303–312. - PubMed

LinkOut - more resources